Company intelligence / Profile preview

Prosonix

Oxford, England, United Kingdompro-sonix.com ↗

Ownership: Private
Employees: ~22
Development stage: Commercial

Overview

Prosonix developed a pipeline of inhaled respiratory medicines using its proprietary ultrasonic particle engineering platform. Its lead products targeted asthma and COPD, with the most advanced program under review by UK regulators at the time of acquisition. The company’s approach enabled precise targeting within the lung and excipient-free formulations for improved efficacy and consistency[1][5].

Therapeutic areas: Pulmonology
Modalities: Small moleculeInhaled drug delivery
Industry: Biotech

Partnerships

Co-development partnerships with leading pharmaceutical companies prior to acquisition. Specific partners not named.

Beyond the preview

Go deeper on Prosonix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prosonix.

Explore the full profile